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A B S T R A C T
Background
Most clinical practice guidelines recommend restrictive red cell transfusion practices, with the goal of minimising exposure to allogeneic
blood (from an unrelated donor). The purpose of this review is to compare clinical outcomes in patients randomised to restrictive
versus liberal transfusion thresholds (triggers).
Objectives
To examine the evidence for the effect of transfusion thresholds on the use of allogeneic and/or autologous blood, and the evidence for
any effect on clinical outcomes.
Search methods
Trials were identified by: computer searches of the Cochrane Central Register of Controlled Trials (the Cochrane Library Issue 3, 2009),
OVID MEDLINE (1966 to August 2009), Current Contents (1993 to November 2004), and the Web of Science (2004 to August
2009). References in identified trials and review articles were checked and experts contacted to identify any additional trials.
Selection criteria
Controlled trials in which patients were randomised to an intervention group or to a control group. Trials were included where
intervention groups were assigned on the basis of a clear transfusion ’trigger’, described as a haemoglobin (Hb) or haematocrit (Hct)
level below which an RBC transfusion was to be administered.
Data collection and analysis
Relative risks of requiring allogeneic blood transfusion, transfused blood volumes and other clinical outcomes were pooled across trials,
using a random effects model. The risk of bias was assessed.
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Main results
Seventeen trials involving a total of 3746 patients were identified. Restrictive transfusion strategies reduced the risk of receiving a red
blood cell (RBC) transfusion by a relative 37% (RR=0.63; 95% CI 0.54 to 0.74). This equates to an average absolute risk reduction
(ARR) of 33% (95% CI 21% to 45%). The volume of RBCs transfused was reduced on average by 0.75 units (95% CI 0.20 to 1.30
units). However, heterogeneity between trials was statistically significant (P<0.001; I²≥74%) for these outcomes. Restrictive transfusion
strategies did not appear to impact on the rate of adverse events compared to liberal transfusion strategies (i.e. mortality, cardiac events,
myocardial infarction, stroke, pneumonia and thromboembolism). Restrictive transfusion strategies were associated with a statistically
significant reduction in the rates of infection (RR=0.76; 95% CI 0.60 to 0.97). The use of restrictive transfusion strategies did not
reduce hospital or intensive care length of stay.
Authors’ conclusions
The existing evidence supports the use of restrictive transfusion triggers in patients who are free of serious cardiac disease. The effects
of conservative transfusion triggers on functional status, morbidity and mortality, particularly in patients with cardiac disease, need to
be tested in further large clinical trials. In countries with inadequate screening of donor blood, the data may constitute a stronger basis
for avoiding transfusion with allogeneic red cells.
P L A I N L A N G U A G E S U M M A R Y
Safety of blood transfusion improved by the use of ’transfusion thresholds’
Many people are given a transfusion of blood from an unrelated donor as part of their medical treatment. There are, however, risks
involved. In particular, infections (including HIV and certain types of hepatitis) may be passed on to the person receiving the blood.
This risk is small in high income countries but much larger in poor countries which lack good facilities to test the blood for infections.
Because of the risks, doctors try to avoid giving blood unless it is really necessary. One approach is to give the transfusion only if the
amount of haemoglobin in the patient’s blood has dropped below a certain ’threshold’ level. The authors looked for controlled studies
evaluating the effectiveness of this approach. They found 17, with a total of 3746 patients. The authors say that more research is needed
and that, until more is known, patients who have a serious heart problem should not be treated in this way. The authors conclude that,
for most patients, blood transfusion is probably not essential until haemoglobin levels drop below 7.0 grammes per decilitre.
B A C K G R O U N D
Blood is an indispensable product in modern medical practice
(Amin 2004). Red blood cells (RBC) are used to improve oxy-
gen delivery to tissues in situations of haemorrhage and anaemia
(Napolitano 2009). Red blood cell transfusion constitutes one of
the mainstays of therapy in the management of anaemic patients
and is one of the few treatments that adequately restore tissue oxy-
genation when oxygen demand exceeds supply (Wang 2010; Klein
2007). Unfortunately the demand for blood products is frequently
far greater than supply. In the United States (US) alone a total of
13.9 million RBC units were transfused to 4.9 million recipients
in 2001 (Sullivan 2007). The Global Database on Blood Supply
(GDBS), established by the World Health Organization (WHO)
in 1997 to address global concerns about the safety and availabil-
ity of blood for transfusion, showed that 80.7 million blood units
were collected globally in 167 countries during 2004-2005 (Takei
2009). In the United Kingdom alone there were approximately
2.8 million whole blood donations and 69,777 apheresis dona-
tions during 2000/2001 (Varney 2003). In the case of sub-Saha-
ran Africa, the WHO estimates that approximately 6.65 million
units of blood are required per year for the region’s population of
around 650 million, however only 2 million units of blood are
currently collected and transfused (Jayaraman 2010).
In developing countries the frequent use of blood transfusion is
often coupled with transfusion services that are not equipped to
conduct universal antibody screening. In sub-Saharan Africa the
median overall risks of becoming infected with HIV, HBV, and
HCV from a blood transfusion have been estimated to be 1.0, 4.3,
and 2.5 infections per 1000 units respectively (Jayaraman 2010).
Based on WHO annual transfusion projections, transfusion alone
would be responsible for 28,595 HBV infections, 16,625 HCV
2Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
infections, and 6,650 HIV infections in this population. Data
modellinghas shown that the risk of acquiringHIV in sub-Saharan
Africa canbe as high as 13 infections per 1000donations compared
to 1 in 1.5 million units in high income countries (Jayaraman
2010).
In most developed countries with well-regulated blood supplies,
the safety of allogeneic red cell transfusion has improved signif-
icantly over the past 30 years. This has been primarily due to
improvements in donor-blood screening procedures and the im-
plementation of more stringent quality control measures (Klein
2007). It has been estimated that the residual risk of transmis-
sion through transfusion of HIV, HCV, and HBV in Canada is 1
per 7.8 million donations, 1 per 2.3 million donations, and 1 per
153,000 donations respectively (O’Brien 2007). Globally, the es-
timated risks of infection per blood unit range from 1 per 100,000
to 1 per 400,000 for HBV, 1 per 1.6 million to 1 per 3.1 million
for HCV, 1 per 1.4 million to 1 per 4.7 million for HIV, and 1 per
500,000 to 1 per 3.0 million for HTLV (Goodnough 2008). Data
from seven countries (Germany, France, Switzerland, Italy, Spain,
United Kingdom, Canada) from 2000-2005 showed the residual
risk of transfusion-transmitted viral infections ranged from 0.22-
2.48 per 1 million donations for HIV, 0.05-3.94 per 1 million
donations for HCV, and 1.51-9.78 per 1 million donations for
HBV (Kitchen 2008).
Blood transfusion services worldwide face an ominous financial
challenge. In Canada, the cost of allogeneic blood transfusion has
almost doubled from 1994/1995 to 2001/2002. Further compar-
isons show that there has been a threefold increase in the cost of
blood distribution and a twofold increase in the cost of blood col-
lection (Amin 2004). The annual cost of collecting, testing, pro-
cessing and issuing blood products in the UK during 2000/2001
was estimated to be around £284 million. The total cost to the
UK National Health Service attributable to blood transfusion in
2000/2001 was estimated to be £898 million with £613.9 million
attributed to in-hospital resource use costs (Varney 2003). The
total expenditures of Canadian Blood Services have risen from an
annualised total of $422 million in 1998/1999 to $638.8 mil-
lion in 2001/2002 with the major cost driver being the cost as-
sociated with measures used to improve the safety of blood trans-
fusion (Wilson 2003). Based on UK and US transfusion data,
the cost of implementing the leukocyte-reduction program in the
US was estimated to be between $400 and $672 million per an-
num (Dzik 2000). In the UK the introduction of universal leuko-
cyte-reduction in 1998 to mitigate the risk of transmitting vari-
ant Creutzfeldt-Jakob disease (vCJD) via blood transfusion was
estimated to cost the National Health Service (NHS) around £70
million per annum (McClelland 2005). In addition to the existing
infectious risks, the threat of new or emerging infection is ever
present (Kitchen 2008). The implementation of new and more
advanced tests to improve the safety of blood transfusion will place
significant pressure on already strained health care budgets. Mea-
sures to reduce the burden of blood transfusion costs on health
care services are continually being sought.
Historically, the widely accepted clinical standard was to trans-
fuse patients when the haemoglobin level dropped below 10.0g/
dL or the haematocrit fell below 30%. This ‘10/30 rule’ was first
proposed by Adams and Lundy in 1942 and served as a RBC
transfusion trigger for decades (Madjdpour 2005; Wang 2010).
However, the 1988 National Institutes of Health Consensus Con-
ference in the United States reported that the evidence did not
support a single criterion for transfusion (NIH 1988). Since then,
several published guidelines have advised against a single thresh-
old for red cell transfusion, recommending that a range of hae-
moglobin values between 6.0 and 10.0g/dL can be used, depend-
ing on the presence of serious co-morbidity (NHMRC & ASBT
2001; BCTMAG 2003; ASA 2006; AAGBI 2008; NBUGI 2001;
Napolitano 2009).
The purpose of the review was to find, appraise and summarise
the data from high-quality trials that studied the clinical impact of
varying thresholds for transfusion with red cells. We were partic-
ularly interested in whether the results of randomised controlled
trials gave support to the trend for increasingly conservative red
cell transfusion practices; in other words that red cell transfusions
can be withheld in some circumstances without harming patients.
O B J E C T I V E S
To examine the evidence on the effect of transfusion thresholds
on the use of red cell transfusions and the evidence for any change
in clinical outcomes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials with a concurrent control group.
Trials were included if the comparison groups were assigned on
the basis of a clear transfusion ’trigger’ or ’threshold’, described as
a haemoglobin or haematocrit level (with or without a specified
level of haemodynamic instability) that had to be reached before a
red cell transfusion was administered. Control group patients were
required to be either transfused with allogeneic and/or autologous
red blood cells at higher Hb or Hct levels (transfusion threshold)
than the intervention group or transfused in accordance with cur-
rent transfusion practices, which may not have included a well
defined transfusion threshold, but involved liberal rather than re-
strictive transfusion practices.
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Types of participants
Trials of surgical or medical patients, involving adults and/or chil-
dren were included.
Types of interventions
The intervention considered was the use of transfusion thresholds
(’triggers’) as a means of guiding allogeneic and/or autologous red
blood cell transfusion.
Types of outcome measures
Primary outcomes
• the proportion of patients ’at risk’ who were transfused with
allogeneic and/or autologous red blood cells, and the amounts of
allogeneic and autologous blood transfused.
Secondary outcomes
• morbidity (non-fatal myocardial infarction, cardiac events,
pulmonary oedema, stroke, thromboembolism, renal failure,
infection, haemorrhage, mental confusion), mortality,
haematocrit levels (post-operative/discharge), and length of
hospital stay (LOS).
Search methods for identification of studies
Electronic searches
The following databases were searched:
• Cochrane Injuries Group Specialised Register (searched 21
August 2009),
• CENTRAL (The Cochrane Library 2009, Issue 3),
• Ovid MEDLINE(R) (1950 to August Week 2, 2009),
• EMBASE (1980 to 2009 Week 33),
• ISI Web of Science: Science Citation Index Expanded (SCI-
EXPANDED) (2004 to August 2009),
• ISI Web of Science: Conference Proceedings Citation Index
- Science (CPCI-S) (2004 to August 2009),
• Current Contents (1993 to November 2004).
The search strategies are presented in Appendix 1.
Searching other resources
Contact was made with experts in the field to identify reports or
projects in progress, relevant to the review. The reference lists of
related reviews and identified articles were checked for relevant
studies. In addition references in the identified trials were checked
and authors contacted, where possible, to identify any additional
published or unpublished data.
Data collection and analysis
Selection of studies
The titles and/or abstracts of the electronic search results were
screened by two authors (one author, KK, for the 2009 update)
to identify trials in which patients were randomised to a restric-
tive transfusion strategy (transfusion threshold and/or protocol),
or to a control group, who were randomised to a liberal transfu-
sion strategy. From the results of the screened electronic searches,
bibliographic searches and contacts with experts, two authors (one
author for the 2009 update) independently selected trials that met
previously defined inclusion criteria. These authors then indepen-
dently extracted study characteristics and outcomes using an ar-
ticle extraction form. The extraction form recorded information
regarding: study type, methodology descriptions, the presence of
a transfusion threshold, transfusion protocol, the type of surgery
involved, clinical setting, treatment outcomes, and general com-
ments. Articles were examined for inclusion/exclusion criteria by
two authors with disagreements resolved by consensus.
Data extraction and management
Articles that met the inclusion criteria were processed for data
extraction. Data were then entered into Review Manager by one
author. Authors of trials were contacted to provide missing data.
A data extraction form was used to record data on the following
outcomes; the number of patients exposed to allogeneic blood,
the amount of allogeneic blood transfused, the number of patients
receiving any transfusion (allogeneic blood, autologous blood, or
both). For trials involving surgical patients, the following out-
comes were recorded; post-operative complications (infection,
haemorrhage, non-fatal myocardial infarction, cardiac events, re-
nal failure, stroke, thromboembolism, pulmonary oedema,mental
confusion),mortality, and length of hospital stay (LOS).Datawere
also be recorded on; blood loss, and, haemoglobin and haematocrit
levels (on admission, pre-post transfusion, at discharge). Informa-
tion regarding, demographics (age, sex), type of surgery or medi-
cal condition was also recorded on the data extraction form. Data
were extracted for allogeneic blood transfusion if it was expressed
as packed red blood cells (RBC). Information regarding the use of
fresh frozen plasma (FFP) and /or platelets was documented.
Assessment of risk of bias in included studies
This was assessed by one author using the Cochrane Collabora-
tion’s tool for assessing risk of bias presented in Higgins 2008.
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The following domains were assessed for each study;
• sequence generation,
• allocation concealment,
• blinding,
• incomplete outcome data.
We completed a risk of bias table for each study, incorporating a
description of the study’s performance against each of the above
domains and our overall judgment of the risk of bias for each
entry as follows; ’Yes’ indicates low risk of bias ’Unclear’ indicates
unclear or unknown risk of bias ’No’ indicates high risk of bias.
Assessment of heterogeneity
Statistical heterogeneity was examined by both the I2 and chi2
tests. The I-squared test describes the percentage of total variation
across studies due to heterogeneity rather than chance. A value of
0% indicates no observed heterogeneity, and larger values show
increasing heterogeneity; substantial heterogeneity is considered
to exist when I²>50% (Higgins 2008). For the chi2 statistic, a P
value of <0.10 was used to indicate the presence of statistically
significant heterogeneity.
Assessment of reporting biases
Funnel plots were examined for evidence of publication bias.
Data synthesis
All analyses were performed using ReviewManager software. Data
on the numbers of patients exposed to allogeneic blood and the
numbers of patients in each treatment group were entered into
Review Manager. The relative risks (RR) for allogeneic blood
transfusion in the intervention group as compared with the con-
trol group, and the corresponding 95% confidence intervals, were
calculated for each trial using the random effects model (Der
Simonian 1986). A similar approach was adopted to examine the
other outcomes of transfusion. The mean number of units of red
blood cells transfused to each group and the corresponding stan-
dard deviations were also entered. The mean difference (MD) and
95% confidence intervals (CI) was used to express the average re-
duction in the number of units of RBC administered to the in-
tervention group, compared with the control. Data in millilitres
(mls) were converted to units by dividing by 300.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were performed to explore treatment effects by
clinical setting, transfusion threshold and adequacy of allocation
concealment.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Included studies
Seventeen eligible studies were identified and are included in this
review.
Of the 17 included trials the clinical settings were variable. Eight
studies took place within the context of surgery− cardiac, vascular
or orthopedic (Bracey 1999; Bush 1997; Carson 1998; Foss 2009;
Grover 2005; Johnson 1992; Lotke 1999; So-Osman 2010). Five
trials were in the context of acute blood loss and/or trauma (Blair
1986; Colomo 2008; Fortune 1987; Topley 1956; Zygun 2009),
three trials involved patients in critical care units (Hebert 1995;
Hebert 1999; Lacroix 2007) and one trial involved leukaemia
patients undergoing chemotherapy or stem cell transplantation
(Webert 2008).
There was considerable variation with regard to the restrictive
transfusion strategies used. These varied from 7.0 to 9.0g/dL,
with two further trials specifying haematocrit values of 25 or 30%
(equivalent to haemoglobin levels of around 8.0 and 10.0g/dL re-
spectively). The liberal transfusion triggers varied from 100% of
’normal red cell volume’ (Topley 1956), two units of blood (im-
mediately in one trial (Blair 1986), post-operatively in another
(Lotke 1999) irrespective of clinical state; transfusion sufficient to
maintain haemoglobin levels at or above 12.0g/dL (Webert 2008),
10.0g/dL (Bush 1997; Carson 1998; Foss 2009; Grover 2005;
Hebert 1995; Hebert 1999), 9.5g/dL (Lacroix 2007), and 9.0g/dL
(Bracey 1999; Colomo 2008; Zygun 2009); two trials specified the
liberal triggers as haematocrit levels of 32% (Johnson 1992) and
40% (Fortune 1987). One trial compared a new uniform, restric-
tive transfusion policy with more liberal standard care (So-Osman
2010).
In these trials random allocation was at the level of the patient, not
the clinician or clinical unit. Consequently, participating clinicians
may have been responsible for patients in both arms of the trials.
Eight trials included more than 100 patients. A total of 3746 trial
participants were included in this systematic review.
Excluded studies
One randomised controlled trial was confined to patients with
sickle cell disease, and was excluded as the trigger was based on the
level of HbS, not the haemoglobin or haematocrit level (Vichinsky
1995).
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Risk of bias in included studies
For further details regarding the performance of the studies against
each domain, please see the ’Risk of bias’ tables. A summary of
the information in the tables is given below. Additionally, a visual
summary of judgements about each methodological quality item
for each included trial is shown in Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Allocation
Adequate sequence generation
The risk of bias for this item was judged to be low for six trials, five
of which used computer randomisation and one used a table of
randomnumbers to allocate patients.One trial based allocation on
hospital record number and was judged to be at high risk of bias,
while the remaining 10 trials presented insufficient information
to assess the adequacy of sequence generation and were rated as
unclear.
Allocation concealment
The risk of bias for this itemwas judged to be low for three trials all
of which used central allocation.Twelve trialswere rated as unclear;
six used sealed envelopes however, it was not clear if they were
used with appropriate safeguards (e.g. sequentially numbered) to
adequately conceal allocation. The other six rated as unclear did
not present any information regarding allocation concealment.
Two trials were rated as being at high risk of bias for this domain.
Blinding
Thenature of the interventionmeans that blinding of clinicians in-
volved in the care and administration of blood transfusions would
not have been feasible, the extent to which this could have biased
the results is unclear, thus none of the studies have been rated as
being at low risk of bias for this domain. However, blind outcome
assessment was reported as being used in six trials.
Incomplete outcome data
Twelve trials were rated as being at low risk of bias for this domain
as they either had no missing data or performed intention-to-
treat analyses. A small number of exclusions were reported in the
remaining five trials although the extent to which this may have
introduced bias is uncertain, thus these trials were rated as unclear.
Effects of interventions
Sixteen of the 17 trials presented data suitable for inclusion in the
pooled analyses.
Despite the heterogeneity in the methods and transfusion triggers
reported in these randomised trials, it was possible to extract and
combine data sets from five or more trials for nine outcomes: ex-
posure to red cell transfusion, exposure to red cell transfusion (al-
logeneic), average volume of red cells transfused in all patients, av-
erage volume of red cells transfused in transfused patients, haema-
tocrit levels, cardiac events, myocardial infarction, mortality at 30
days, and length of hospital stay.
Red cell transfusion
Data on the frequency of transfusions were extractable from 15
trials. On average, the implementation of a restrictive transfusion
trigger reduced the risk of receiving a red cell transfusion by a rel-
ative 37% (RR=0.63; 95% CI 0.54 to 0.74). Heterogeneity be-
tween these trials was statistically significant (chi²=123.82, df=14,
P<0.00001; I²=89%). The quantities of blood transfused were re-
ported in eight trials. The use of a restrictive transfusion trigger
resulted in an average saving of 0.75 units of red cells per trans-
fused patient (MD=-0.75; 95% CI -1.30 to -0.20). Heterogeneity
between these trials was statistically significant (chi²=27.05, df=7,
P=0.0003; I²=74%).
Haemoglobin/Haematocrit levels
Post-operative haemoglobin or haematocrit levels were reported
for nine trials. However, the timing of measurement varied, being
the average measured over a number of days after hospitalisation
(or operation) in four trials, a single value prior to discharge in
four trials and a single value after the first transfusion in one trial.
When data were pooled (without regard to timing, which was con-
sistent within studies), patients assigned to a restrictive strategy
had haematocrit levels on average 4.7% (MD= -4.69; 95% CI -
6.71 to -2.67) lower than patients assigned to a liberal transfusion
strategy. Heterogeneity between these trials was statistically signif-
icant (chi²=463.96, df=8, P<0.00001; I²=98%).
Mortality
Thirty-day mortality data were reported for nine trials. There was
no statistically significant difference in 30-day mortality between
restrictive and liberal transfusion strategies (RR=0.83; 95% CI
0.66 to 1.05). Heterogeneity between these trials was not statis-
tically significant (chi²=5.09, df=7, P=0.65; I²=0%). It should be
noted that one study of patients in intensive care (Hebert 1999)
contributed 75% of the weight in the meta-analysis of this out-
come.
Hospital length of stay
Seven trials reported data on length of hospital stay. These data
indicated that the reduction in red blood cell transfusion was not
associated with a prolongation in hospital stay (MD= -0.39 days;
95% CI -0.91 to 0.13 days). Heterogeneity between these trials
was not statistically significant (chi²=1.40, df=6, P=0.97; I²=0%).
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Cardiac events
Five trials reported data on cardiac events. The rates of cardiac
events (myocardial infarction, cardiac arrhythmias, cardiac arrest,
pulmonary oedema and angina) were not increased significantly by
the use of restrictive transfusion strategies (RR=0.76; 95%CI 0.57
to 1.00). Heterogeneity between these trials was not statistically
significant (chi²=4.87, df=4, P=0.30; I²=18%).
Myocardial infarction
Seven trials reported data on myocardial infarction. The use of a
restrictive transfusion threshold did not appear to impact adversely
on the rates of myocardial infarction (RR=0.50; 95% CI 0.21 to
1.21). There was no evidence of statistical heterogeneity between
trials (chi²=5.05, df=6, P=0.54; I²=0%).
Infections
Four trials reported data on infections. The rate of infections was
decreased by a relative 24% with the use of restrictive transfusion
strategies (RR=0.76; 95% CI 0.60 to 0.97). Heterogeneity be-
tween these trials was not statistically significant (chi²=2.74, df=
3, P=0.43; I²=0%).
Other outcomes
A number of other potentially relevant clinical outcomes were re-
ported in individual trials, including stroke, thromboembolism,
multi-organ failure, mental confusion, and delayed wound heal-
ing. Although there were no statistically significant differences be-
tween restrictive and liberal transfusion strategies for any of these
outcomes the overall event rates were low. Interestingly, one trial
(Blair 1986) reported a decreased risk of re-bleeding in patients
randomised to a restrictive transfusion strategy compared to pa-
tients randomised to a liberal transfusion strategy (RR=0.10; 0.01
to 0.75). Where reported, heart rates, cardiac index, and systemic
vascular resistance also appeared to be unaffected (Bush 1997;
Johnson 1992).
Sensitivity analyses
A post hoc sensitivity analysis was performed to explore the effects
of the inclusion of data from the Webert 2008 trial in the pooled
analyses. Webert 2008 explored whether a higher transfusion
threshold would be beneficial for patients with acute leukaemia,
unlike the other included studies which investigated the safety of
a lower transfusion threshold. When data fromWebert 2008 were
excluded from the pooled analysis blood transfusion exposure, the
relative risk was reduced slightly from 0.63 (95% CI 0.54 to 0.74)
to 0.61 (95% CI 0.53 to 0.71). Heterogeneity between these trials
remained statistically significant (chi²=96.82, df=13, P<0.00001;
I²=87%).
D I S C U S S I O N
We identified 17 randomised clinical trials evaluating different red
cell transfusion triggers carried out over a 55-year time period.
These trials enrolled 3746 patients from divergent patient popula-
tions. The results of the meta-analyses indicated that, on average,
conservative transfusion strategies were associatedwith a reduction
of more than one third in the number of patients receiving blood,
a red cell transfusion requirement that was approximately one unit
lower, and haematocrit values (average post-operative) that were
around 5% lower than in the liberal transfusion group. However,
such results need tempering against the significant heterogeneity
of the trials assessed.
Sources of heterogeneity
For the main outcomes (the number of patients exposed to blood
transfusion, and the amount of blood transfused) substantial het-
erogeneity was observed. The variation was in terms of the size
(but not the direction) of the treatment effect. The individual trials
(with five exceptions - Bush 1997, Grover 2005; So-Osman 2010;
Topley 1956 and Webert 2008) found that a conservative trans-
fusion trigger statistically significantly reduced the probability of
receiving a red cell transfusion with the relative risk estimates rang-
ing from 0.21 to 0.96. However, some confidence intervals were
non-overlapping. Heterogeneity might have been anticipated, as
the clinical settings and the transfusion triggers differed between
trials. In addition, the primary outcome in the meta-analysis −
the decision to transfuse − is a practice variable, and involves a
degree of subjectivity. It cannot be argued that the treatment effect
varied according to the rate of red cell transfusion in the control
groups, as most patients (78%) in the liberal transfusion groups
received red cell transfusions.
The level of the transfusion trigger between trials does not seem to
account for the variation in treatment effect size; the relative risk
appeared unrelated to it. However, the degree of difference within
trials, between the transfusion triggers of the intervention and
control groups may account for some of the variation observed in
the treatment effect size. The effect estimates for trials comparing
well-defined transfusion rates that differed by 2.0g/dL tended to be
larger than the estimates for trials comparing thresholds differing
by less than 2.0g/dL. Although these apparent ’associations’ may
also be due to the play of chance, such observationswarrant further
discussion.
Two trials (Blair 1986; Lotke 1999) showed greater benefit (in
favour of restrictive transfusion strategies) in reducing exposure to
red cell transfusion, than any of the other trials. These two trials
appeared to be adding considerably to the observed heterogene-
ity. In Blair 1986 the control group were routinely transfused (as
dictated by the trial protocol) at least two units of blood within
24 hours of hospital admission, regardless of their Hb level and
clinical state, whereas the intervention group were only transfused
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blood when their Hb concentration fell below 8.0g/dL or they
displayed signs of shock. For this trial (Blair 1986) the transfu-
sion exposure rate for the intervention group was 19% compared
to 100% for the control group. For the trial conducted by Lotke
1999 the control group received all of their pre-operatively do-
nated autologous (PAD) blood (2 units/patient) immediately after
surgery (as dictated by the trial protocol) whereas the patients in
the intervention group were not transfused their PAD blood un-
less their Hb concentration fell to less than 9.0g/dL. For this trial
(Lotke 1999) the transfusion exposure rate for the intervention
group was 26% compared to 100% for the control group.
Five trials (Bush 1997; Grover 2005; So-Osman 2010; Topley
1956; Webert 2008) failed to show a statistically significant re-
duction in red cell transfusion rates. For Bush 1997 and Webert
2008 protocol violations may have impacted significantly on the
rates of transfusion in the intervention groups. In Bush 1997,
patients randomised to the intervention group were to be trans-
fused allogeneic red cells, and in some instances autologous red
cells, when their Hb concentration fell below 9.0g/dL, the con-
trol group were transfused when their Hb concentration fell below
10.0g/dL. The authors of Bush 1997 conceded that not all the
patients randomised to the restrictive transfusion strategy reached
the transfusion threshold level of Hb <9.0g/dL because they either
had minimal intra-operative blood loss or were excessively trans-
fused by the anaesthetists or surgeons. The later may account for
the relatively small difference in transfusion rates between the in-
tervention and control groups (88% versus 80%, respectively). In
Webert 2008, patients were allocated to receive RBC transfusion
when their Hb level fell below 8.0 g/dL in the intervention group
or 12.0g/dL in the control. The trial authors note that a num-
ber of patients received transfusion before their assigned thresh-
old had been reached; compliance with the assigned threshold was
achieved only 64% of the time in the intervention and 70% of the
time in the control group. This also may explain the similar trans-
fusion rates observed in the two groups (90% and 94% for the
restrictive and liberal groups, respectively). The trial by So-Osman
2010 compared a new age-dependent restrictive transfusion policy
with the standard policy used in the three participating hospitals.
Deviation from the assigned trigger was not found to be a prob-
lem, however differences in the transfusion threshold forming the
standard policy of the hospitals may explain the lack of difference
observed in transfusion rates (36% and 39% for intervention and
control, respectively). The trial by Topley 1956 was designed so
that one group of patients (’Under-transfused’ group) would have
a red cell volume (RCV) of 70-80% of normal at the end of resus-
citation, whilst the control group (’Adequately transfused’ group)
would have a RCV of 100% of normal or over at the end of resus-
citation. However, as reported, in practice these objectives were
achieved with an accuracy of only ±20%.
The most common and disturbing feature of the trials reviewed
here was the high rates of transfusion amongst the control groups.
Of the 15 trials that provided data on the proportion of patients
transfused blood (allogeneic and/or autologous blood), 11 trials
had blood transfusion rates in excess of 88% for the control group.
For five of these 11 trials, the control group had red cell transfusion
rates of 100%. In summary, these high transfusion rates in the con-
trol groups may be explained by the following: (1) clinical setting
- eight trials involved trauma or critically ill patients (a subgroup
of patients at greater risk of developing anaemia due the nature of
their injury or illness); (2) the transfusion threshold used - in the
majority of trials the control groups were transfused when their
Hb concentration fell below 10.0 g/dL (a relatively high threshold
bymodern standards); and (3) pre-operatively donated autologous
(PAD) blood was used - in one trial (Bush 1997) PAD blood was
used in conjunction with allogeneic red cell transfusion, and in
two trials (Johnson 1992; Lotke 1999) PAD was used exclusively.
There is no evidence to suggest that clinical setting or adequacy
of allocation concealment explains the variability in the effect es-
timates.
Adverse events and other outcomes
Mortality, cardiac morbidity, and length of hospital stay did not
appear to be adversely affected by the lower use of red cell trans-
fusions. Although these data are quite informative, and tend to
support the recent move to more restrictive transfusion practices,
they are insufficient to address our main research questions, which
concerned the benefits and harms associated with different trans-
fusion thresholds, particularly in patients with serious co-existing
disease. Although very little heterogeneity was seen for the out-
come variable, mortality, the meta-analysis was dominated by one
trial (Hebert 1999) that contributed 75% of the statistical infor-
mation.
Sources of bias
We performed extensive searches in an attempt to identify all eli-
gible trials irrespective of publication status. Despite these efforts,
inspection of the funnel plot (Figure 2) suggests the possibility
of publication bias or other small study biases affecting the expo-
sure to blood transfusion outcome. Publication bias leading to the
exclusion of small studies with non-significant results, may lead
to an over-estimate of treatment effect. However, the existence of
true heterogeneity should be considered as a potential explanation
for the funnel plot asymmetry.
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Figure 2. Funnel plot of comparison: 3.1 Patients exposed to blood transfusion (all studies).
Our analyses demonstrate that only one trial (Hebert 1999) was
adequately powered to evaluate the impact of different transfusion
strategies onmortality and morbidity. Hebert 1999 was the largest
study, involving 838 intensive care patients. Given this, the meta-
analysis ofmortality is dominated by a study of patients in intensive
care, and therefore it is uncertain if the results can be applied to
other clinical settings.
Several important clinical outcomes have not been evaluated in
the trials published to date. We have previously hypothesised that
liberal transfusion may improve functional recovery and reduce
nursing home placement in elderly hip fracture patients (Carson
1998). Observational data suggest that higher blood counts may
be associated with less post-operative delirium (Weiskopf 2000).
This systematic review found minimal evidence of the safety of
conservative transfusion triggers in important subsets of patients,
including those with severe cardiovascular disease, renal failure,
and haematological disorders. The results of two small observa-
tional studies, one involving patients with vascular disease (Nelson
1993) and the other involving patients undergoing radical prosta-
tectomy (Hogue 1998), suggest improved outcome with a lib-
eral transfusion trigger. These findings are consistent with animal
data (Hagl 1977; Wilkerson 1988; Yoshikawa 1973) and a study
in patients who declined blood transfusion for religious reasons,
which showed highermortality in patients with cardiovascular dis-
ease than patients without cardiovascular disease as the haemo-
globin level fell below 10.0g/dL (Carson 1996). Overall, the rates
of cardiac events in this meta-analysis were not increased by the
use of conservative transfusion triggers. However, other than one
relatively small study in patients having coronary artery bypass
surgery, it is unclear how many patients with established cardiac
diseases were included in these trials.
Although some guidelines recommend transfusion for symptoms
of haemodynamic instability, rather than for a specific trigger
haemoglobin level (AAGBI 2008; ASA 2006; NBUGI 2001;
NHMRC & ASBT 2001; Napolitano 2009), we found only one
small pilot study of 84patients that evaluated this transfusion strat-
egy (Carson 1998). This study found a non-significant increase in
mortality in patients in the symptomatic transfusion group.
The results of these trials need to be viewed against four large
observational studies that compared clinical outcomes at varying
haemoglobin levels in transfused and non-transfused patients, and
found conflicting results. In a study of 2202 patients undergo-
ing coronary bypass surgery, the liberal transfusion group had a
higher incidence of myocardial infarction than the conservative
transfusion group (Spiess 1998). In a study of 8787 hip fracture
patients, there was no difference in short or long-term mortality
between patients transfused and not transfused down to a post-
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operative haemoglobin of 8.0 g/dL (Carson 1998). In a study of
4470 ICU patients, mortality was reduced in patients receiving
transfusion of up to six units of blood (Hebert 1997). A retrospec-
tive study of 78,974Medicare beneficiaries (Wu 2001), found that
blood transfusion was associated with a lower short-term mortal-
ity rate among elderly patients with acute myocardial infarction if
the haematocrit on admission was 30% or lower and that blood
transfusion may be effective with a haematocrit as high as 33%
on admission. The main limitation of these observational studies
is that there may be residual confounding by indication, despite
the extensive statistical adjustment of the results. It is possible that
differences in patient characteristics between transfused and non-
transfused patients may not be identified, or adequately adjusted
for. This point is emphasized by the fact that a randomised con-
trolled trial (Hebert 1999) and an observational study (Hebert
1997) in intensive care patients, performed by the same group,
came to opposite conclusions.Despite recent assertions to the con-
trary (Benson 2000; Concato 2000), we believe that adequately
powered, rigorously performed, randomised clinical trials are the
only way of overcoming these limitations.
A study (Henry 2001a) presented at the Cochrane Colloquium
in Lyon, France (9-13 October, 2001), highlighted the significant
discrepancies in the results reported by randomised controlled tri-
als compared to those reported by observational studies. This and
other studies (Ioannidis 2001) have shown that disagreements in
the magnitude of treatment effect between RCTs and observa-
tional studies are common. The authors of Henry 2001a analysed
the data from studies of various interventions including; pre-oper-
ative autologous donation (PAD), acute normovolemic haemod-
ilution, cell salvage, laparoscopic cholecystectomy, hormone re-
placement therapy, and antioxidant therapy. For PAD alone, the
observational studies (n=41) estimate of treatment effect (relative
risk), for the number patients exposed to allogeneic blood trans-
fusion, was 0.30 (95% CI 0.26 to 0.35) compared to 0.39 (95%
CI 0.27 to 0.57) for the RCTs (n=7). For this intervention (PAD),
there appears to be reasonable agreement between the results of the
observation studies and the randomised controlled trials. How-
ever, the observational studies have appeared to over-estimate the
magnitude of treatment effect. Observational studies of the other
interventions tended to under-estimate the magnitude of treat-
ment effect. Although the results obtained from well conducted
observational studies are extremely valuable, making inferences
from observational data sets is problematic, as the sources of error
and bias that afflict observational studies do not afflict randomised
trials (Henry 2001a).
Conducting randomised clinical trials, where one intervention is a
clinical policy regarding red cell transfusion, is demanding. Mask-
ing the use of transfusion at the bedside is difficult to achieve unless
study personnel are assigned to each patient, an expensive proce-
dure. Outcomes that are determined by observers who are blind to
the treatment group is probably the most rigorous approach that
is practical. This approach was reported in only six of the trials
reviewed here (Carson 1998; Grover 2005; Foss 2009; Johnson
1992; Lotke 1999; Webert 2008). Maintaining the integrity of
the randomisation process becomes important if the trial is not to
over-estimate the benefit of the intervention (Schulz 1995). Some
studies in this review did not report the methods used to conceal
the allocation sequence from the treating clinicians. Three trials
(Carson 1998; Lacroix 2007; Webert 2008) used a centralised al-
location, and four others (Bush 1997; Foss 2009; Hebert 1999;
So-Osman 2010) used randomisation codes in sealed envelopes.
The latter method has the potential to be unmasked, leading to
the potential for selection bias in the inclusion of patients in the
trials (Schulz 1995).
The transfusion policies reviewed here represent fairly small mod-
ifications to routine clinical practice. They are consistent with
the recommendations of published clinical practice guidelines
(AAGBI 2008; ASA 2006; BCTMAG 2003; NBUGI 2001;
NHMRC&ASBT2001;Napolitano 2009). The transfusion trig-
gers (in terms of haemoglobin levels) were most often in the range
of 8.0 to 9.0g/dL, although values as low as 7.0g/dL were assessed.
In fact, the ’restrictive’ transfusion triggers in some trials were
equivalent to the ’liberal triggers’ used in other trials. Nevertheless,
the trials documented significant reductions in the rates of red cell
transfusion, and worthwhile blood conservation. These effects are
similar to what has been documented in meta-analyses of trials of
blood sparing techniques, such as cell salvage and anti-fibrinolytic
drugs (Carless 2010; Henry 2001b). Adoption of a conservative
transfusion threshold appears to be as effective as these technolo-
gies in avoiding the need for transfusion, and is likely to cost less.
In summary, a conservative transfusion trigger reduces the risk of
exposure to red blood cell transfusion and the total number of
units transfused. The currently published evidence suggests that
conservative transfusion triggers do not adversely affect mortality,
cardiac morbidity, or length of hospital stay. Given the uncertain
generalisability of the data across different clinical settings, the
limited data from patients with underlying cardiovascular disease,
and the absence of data on functional recovery, we suggest that
additional randomised clinical trials should be undertaken. For
the present we recommend the use of a conservative transfusion
trigger, but suggest using caution in patients with cardiovascu-
lar disease. In countries where there are serious doubts about the
safety of donated blood, because of inadequate testing for viral
pathogens, the existing data may constitute a stronger basis for
avoiding red cell transfusion in many clinical settings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients who do not have advanced coronary artery disease,
blood transfusion can probably be withheld in the presence of
haemoglobin levels as low as 7.0g/dL so long as there is no notable
bleeding.The benefits ofminimising allogeneic red cell transfusion
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are likely to be greatest where there is doubt about the safety of
the blood supply.
Implications for research
Future trials of transfusion ’triggers’ should include patients with
cardiac and renal disease, and should be large enough to measure
the impact that lower thresholds have on clinical outcomes, in-
cluding functional status.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Blair 1986
Methods Randomised controlled trial.
Participants 50 consecutive patients with severe upper gastrointestinal haemorrhage were randomised
to one of two groups:
• Liberal group: n = 24; mean (sd) age = 64 (17.6) years
• Restrictive group: n = 26; mean (sd) age = 60 (17.8) years
Interventions • Liberal group received at least 2 units of red blood cells immediately at admission
and during their first 24 hours in hospital.
• Restrictive group were not transfused red blood cells unless the Hb was less than
8.0g/dL or shock persisted after initial resuscitation with Haemaccel.
Outcomes Outcomes reported: blood usage (units), re-bleeding, mortality, clotting times, Hct on
admission/discharge, kaolin cephalin clotting time after 24 hours, impedance clotting
time after 24 hours
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information reported.
Allocation concealment? Unclear No information reported.
Blinding?
All outcomes
Unclear No information reported.
Incomplete outcome data addressed?
All outcomes
Yes No missing data.
Bracey 1999
Methods Randomised controlled trial.
Participants 428 consecutive patients undergoing elective primary coronary artery bypass graft surgery
were randomly assigned to one of two groups:
• Liberal group: n = 212; M/F = 82/18; mean (sd) age = 61 (11) years
• Restrictive group: n = 216; M/F = 83/17; mean (sd) age = 62 (11) years
Interventions • Liberal group received transfusions on the instructions of their individual
physicians, who considered the clinical assessment of the patient and the institutional
guidelines, which propose a Hb level <9.0g/dL as the postoperative threshold for RBC
17Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bracey 1999 (Continued)
transfusion.
• Restrictive group received an RBC transfusion in the postoperative period at a Hb
level <8.0g/dL.
Outcomes Outcomes reported: mortality, length of hospital stay, blood usage (units), blood loss,
complications, infection rates, cardiac events
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Patients were randomly assigned on the basis of the last
digit of their medical record number
Allocation concealment? No Inadequately concealed (record number).
Blinding?
All outcomes
Unclear No information.
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used. A small numbers of ex-
clusions were reported
Bush 1997
Methods Randomised controlled trial.
Participants 99 patients undergoing elective aortic or infrainguinal arterial reconstruction were ran-
domised to one of two groups:
• Liberal group: n = 49; M/F = 41/8; mean (sd) age = 64 (11) years
• Restrictive group: n = 50; M/F = 32/18; mean (sd) age = 66 (10) years
Interventions • Liberal group had their Hb concentrations maintained at or above 10.0g/dL.
• Restrictive group were transfused only when their Hb concentration fell below 9.
0g/dL
Outcomes Outcomes reported: 30-day mortality, length of ICU stay, length of hospital stay, blood
use (units), post-operative blood loss, cardiac events, Hct/Hb on admission
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information.
18Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bush 1997 (Continued)
Allocation concealment? Unclear Sealed envelopes were chosen at random for patient as-
signment
Blinding?
All outcomes
Unclear Both surgeons and anaesthesiologists were informed as
to the group of randomisation
Incomplete outcome data addressed?
All outcomes
Yes Appears to be complete.
Carson 1998
Methods Randomised controlled trial.
Participants 84 hip fracture patients undergoing surgical repair who had postoperative Hb levels <10.
0 g/dL were randomly assigned to one of two groups:
• Liberal group: n = 42; M/F = 9/33; mean (sd) age = 81.3 (8.1) years
• Restrictive group: n = 42; M/F = 11/31; mean (sd) age = 83.3 (10.8) years
Interventions • Liberal group received 1 unit of packed RBC at the time of random assignment
and as much blood as necessary to keep the Hb level above 10.0g/dL.
• Restrictive group received a RBC transfusion for symptoms of anaemia or for a
Hb level that dropped below 8.0g/dL.
Outcomes Outcomes reported:mortality, length of hospital stay, bloodusage (units), complications,
pneumonia, stroke, thromboembolism
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation schedules were stratified by clinical site
and cardiovascular disease state. The randomisation was
designed in blocks of 2-8 patients to avoid imbalance
within a site
Allocation concealment? Yes Study personnel at the clinical sites randomly assigned
patients by contacting the data coordinating centre’s 24-
hour automated telephone service
Blinding?
All outcomes
Unclear Blinding of observers.
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used.
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Colomo 2008
Methods Randomised controlled trial.
Participants 214 patients with acute gastrointestinal bleeding and cirrhosis were randomly allocated
to one of two groups:
• Liberal group: n = 105
• Restrictive group: n = 109
NB: No demographic information were presented, although stated that baseline charac-
teristics were similar in the two groups
Interventions • Liberal group received packed RBC when Hb level dropped below 9.0g/dL (to
maintain Hb concentration at 9.0-10.0 g/dL).
• Restrictive group received packed RBC when Hb level dropped below 7.0g/dL (to
maintain Hb concentration at 7.0-8.0g/dL).
Outcomes Outcomes reported: mortality, therapeutic failures, transfusion, Hb concentration, side
effects
Notes Conference abstract.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information
Allocation concealment? Unclear No information
Blinding?
All outcomes
Unclear No information
Incomplete outcome data addressed?
All outcomes
Unclear Insufficient information presented to permit judgement
of ’Yes’ or ’No’
Fortune 1987
Methods Randomised controlled trial.
Participants 25 patients were studied prospectively following acute injury and haemorrhage. These
patients were randomised to one of two groups:
• Liberal group: n = 13; mean age = 46.9 years
• Restrictive group: n = 12; mean age = 46.5 years
Interventions • Liberal group had their Hct brought up to 40% slowly over a period of several
hours by the infusion of packed red cells.
• Restrictive group had their Hct maintained close to 30% by the appropriate
administration of packed red cells.
NB: All patients had sustained a Class III or Class IV haemorrhage and had clinical signs
of shock (systolic bloodpressure <90 torr, heart rate >100bpm, or urine output <20ml/hr)
before entry into the study. Patients were resuscitated according to the clinical protocol
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Fortune 1987 (Continued)
of the centre first using crystalloid to re-establish organ perfusion and haemodynamic
stability and then giving sufficient packed red cells to achieve aHct close to 30%. Patients
were studied twice a day for 3 days after the period of haemorrhagic shock
Outcomes Outcomes reported: RBC consumption (units), cardiopulmonary parameters: pul-
monary capillary wedge pressure (PCWP), Intrapulmonary shunt, Tissue oxygenation /
perfusion, Oxygen consumption/delivery, Arterial and venous O2 saturations, Arterial
and venous O2 contents, Cardiac index (CI), Heart rate, Systemic vascular resistance,
Left ventricular stroke work index
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information.
Allocation concealment? Unclear No information.
Blinding?
All outcomes
Unclear No information.
Incomplete outcome data addressed?
All outcomes
Yes Appears to have been complete.
Foss 2009
Methods Randomised controlled trial.
Participants 120 hip fracture patients were randomly allocated to one of two groups:
• Liberal group: n = 60; M/F = 14/46; mean (sd) age = 81 (6.8) years
• Restrictive group: n = 60; M/F = 14/46; mean (sd) age = 81 (7.3) years
Interventions • Liberal group received packed RBC when Hb level dropped below 10.0g/dL.
• Restrictive group received packed RBC when Hb level dropped below 8.0g/dL.
Outcomes Outcomes reported: ambulatory capacity, mortality, length of stay, cardiac complica-
tions, infectious complication
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated list.
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Foss 2009 (Continued)
Allocation concealment? Unclear Sealed envelopes.
Blinding?
All outcomes
Unclear Reported as being double-blind.
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used.
Grover 2005
Methods Randomised controlled trial.
Participants 260 patients undergoing elective lower limb joint replacement surgery were randomly
allocated to one of two groups:
• Liberal group: n = 109; M/F = 55/54; mean (sd) age = 71.5 (7.6) years
• Restrictive group: n = 109; M/F = 48/61; mean (sd) age = 70.7 (7.1) years
Interventions • Liberal group received packed RBC when Hb level dropped below 10.0g/dL, and
Hb concentration maintained between 10.0-12.0 g/dL.
• Restrictive group received packed RBC when Hb level dropped below 8.0g/dL
and Hb concentration maintained between 8.0-9.5 g/dL.
Outcomes Outcomes reported: ischaemic load, blood load, Hb concentration, number of units
transfused, length of hospital stay, adverse events, new infections requiring antibiotic
therapy
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table.
Allocation concealment? Unclear Sealed envelopes.
Blinding?
All outcomes
Unclear Anaesthetists and surgical team responsible for treatment
were aware of allocation. Outcome assessment was blind
Incomplete outcome data addressed?
All outcomes
Unclear Of a recruited 260 patients, outcome data presented for
218. Missing 42 did not have analysable tape recordings
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Hebert 1995
Methods Randomised controlled trial.
Participants 69 normovolaemic critically ill patients admitted to one of five tertiary level intensive care
units with Hb values <9.0g/dL within 72 hours of admission were randomly assigned to
one of two groups:
• Liberal group: n = 36; M/F = 19/17; mean (sd) age = 59 (21) years
• Restrictive group: n = 33; M/F = 14/19; mean (sd) age = 58 (15) years
Interventions • Liberal group were transfused RBC if the Hb level fell to between 10.0-10.5 g/dL.
Hb level maintained between 10.0-12.0 g/dL.
• Restrictive group were transfused RBC if the Hb level fell to between 7.0-7.5 g/
dL. Hb level was maintained between 7.0-9.0 g/dL.
Outcomes Outcomes reported: mortality, length of hospital stay, length of ICU stay, blood usage
(units), complications, Hb levels
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were assigned to one of two groups by consecu-
tive allocation from a random listing stratified by centre
and disease severity
Allocation concealment? Unclear No information.
Blinding?
All outcomes
Unclear “Blinding of treatment allocation was not feasible”.
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used.
Hebert 1999
Methods Randomised controlled trial.
Participants 838 critically ill patients with euvolemia after initial treatment who had Hb concentra-
tions <9.0g/dL within 72 hours after admission to the intensive care unit were randomly
assigned to one of two groups:
• Liberal group: n = 420; M/F = 255/165; mean (sd) age = 58.1 (18.3) years
• Restrictive group: n = 418; M/F = 269/149; mean (sd) age = 57.1 (18.1) years
Interventions • Liberal group were transfused RBC when the Hb concentration fell below 10.0g/
dL. The Hb concentration was maintained between 10.0-12.0g/dL.
• Restrictive group were transfused RBC if the Hb concentration dropped below 7.
0g/dL. The Hb concentration was maintained between 7.0-9.0g/dL.
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Hebert 1999 (Continued)
Outcomes Outcomes reported: mortality, length of hospital stay, length of ICU stay, blood usage
(units), complications, infection rates, cardiac events, pulmonary oedema, pneumonia
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random order.
Allocation concealment? Unclear Sealed, opaque envelopes prepared by the data-coordi-
nating centre and distributed to each participating insti-
tution where they were opened up sequentially to deter-
mine the patients treatment assignment. The envelopes
were returned periodically to the coordinating centre for
auditing
Blinding?
All outcomes
Unclear “It was not feasible to mask the assigned transfusion
strategy from health care providers”
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used.
Johnson 1992
Methods Randomised controlled trial.
Participants 39 autologous blood donors undergoing elective myocardial revascularisation were ran-
domised to one of two groups:
• Liberal group: n = 18; M/F = 16/2; mean (sd) age = 60.5 (6.9) years
• Restrictive group: n = 20; M = 20; mean (sd) age = 58.2 (7.5) years
Interventions • Liberal group received blood to achieve a Hct value of 32%.
• Restrictive (conservative) group received transfusions for a Hct value less than
25%.
NB: Operative management included sequestration of one or more units of fresh autol-
ogous blood in patients with a Hct value greater than 35% who were haemodynamically
stable after anaesthetic induction. Red cell conservation was practiced through salvage
of oxygenator contents and reinfusion of postoperatively shed mediastinal blood. On
the 5th postoperative day all patients were asked to complete an exercise treadmill test.
A second test was performed the following day
Outcomes Outcomes reported: cardiac events, complications, post-operative blood loss, blood use
(total units), allogeneic blood use (units), autologous blood use (units), all product blood
use (units), number of patients receiving transfusions,mean cardiac index,mean systemic
resistance, exercise capacity, Hct levels, length of ICU stay, length of hospital stay
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Johnson 1992 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomised with the aid of a table of random numbers
and an odd-even designation
Allocation concealment? No Inadequately concealed.
Blinding?
All outcomes
Unclear Surgeons and anaesthesiologists were blinded as to the
group of randomisation until the patient reached the
intensive care unit (ICU)
Incomplete outcome data addressed?
All outcomes
Unclear A small number of exclusions were reported.
Lacroix 2007
Methods Randomised controlled trial.
Participants 637 stable, critically ill children with Hb concentrations below 9.5g/dL within 7 days
after admission to an ICU were randomly allocated to one of two groups:
• Liberal group: n = 317; M/F = 191/126; mean (sd) age = 39.6 (51.9) months
• Restrictive group: n = 320; M/F = 190/130; mean (sd) age = 35.8 (46.2) months
Interventions • Liberal group were transfused RBC when the Hb concentration fell below 9.5g/
dL, with a target range of 11.0-12.0g/dL.
• Restrictive group were transfused RBC if the Hb concentration dropped below 7.
0g/dL, with a target range of 8.5-9.5g/dL.
Outcomes Outcomes reported: 28-day mortality, sepsis, transfusion reactions, infections, length of
stay
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information.
Allocation concealment? Yes Internet-based, central allocation.
Blinding?
All outcomes
Unclear Clinical staff and parents of the patients were aware of
the assignments to study groups, but the statistician and
members of the data and safety monitoring committee
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Lacroix 2007 (Continued)
were unaware of the assignments
Incomplete outcome data addressed?
All outcomes
Yes Intention-to-treat analysis used.
Lotke 1999
Methods Randomised controlled trial.
Participants 152 patients undergoing primary total knee arthroplasty (TKA) were randomly assigned
to one of two groups:
• Liberal group: n = 65; M/F = 19/46; mean age = 69.7 years
• Restrictive group: n = 62; M/F = 20/42; mean age = 68.7 years
Interventions • Liberal group were transfused autologous blood immediately after TKA,
beginning in the recovery room postoperatively.
• Restrictive group were transfused autologous blood when the Hb level had fallen
to <9.0g/dL.
Outcomes Outcomes reported: complications, cardiac events,Hb levels, bloodusage (units),mental
confusion, lethargy, orthostatic hypotension, number of patients transfused
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer random number generator.
Allocation concealment? Unclear Not reported.
Blinding?
All outcomes
Unclear Assessments were made by a person blind to the group
to which the patient was assigned
Incomplete outcome data addressed?
All outcomes
Unclear Appears to have been complete.
So-Osman 2010
Methods Randomised controlled trial.
Participants 619, patients undergoing elective orthopaedic hip/knee replacement surgery were ran-
domised to one of two groups:
• Liberal (Standard care) group: n = 304; M/F = 118/186; mean (sd) age = 70.3 (9.
7) years
• Restrictive (New transfusion policy) group: n = 299; M/F = 84/215; mean (sd)
age = 70.7 (10.2) years
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So-Osman 2010 (Continued)
Interventions • Liberal group received standard care.
• Restrictive group were treated using a ’New transfusion policy’.
Outcomes Outcomes reported: red blood cell usage, length of hospital stay, Hb levels, mobilisation
delay, post-operative complications
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information.
Allocation concealment? Unclear Sealed opaque envelopes.
Blinding?
All outcomes
Unclear Clinicians caring for the patientswere aware of allocation
status, however, the study investigators were not
Incomplete outcome data addressed?
All outcomes
Unclear Intention-to-treat analysis was not performed, although
unclear if this would has biased the results
Topley 1956
Methods Randomised controlled trial.
Participants 22 trauma patients were randomly allocated to one of two groups:
• Liberal group: n = 10
• Restrictive group: n = 12
NB: No demographic data were reported.
Interventions • Liberal group: the aim was to achieve 100 per cent or more of the red cell volume
at the end of resuscitation.
• Restrictive group: an attempt was made to leave the red cell volume at the end of
resuscitation at 70-80 percent of normal.
Outcomes Outcomes reported: blood usage (units), blood loss, wound healing, elevated tempera-
ture, number of patients transfused, Hb levels
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear When the patient was considered eligible for the trial,
they were placed in a severity grade and an envelope
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Topley 1956 (Continued)
opened to decide which transfusion schedule was to be
used
Allocation concealment? Unclear Sealed envelopes.
Blinding?
All outcomes
Unclear No information.
Incomplete outcome data addressed?
All outcomes
Yes Appears to be complete.
Webert 2008
Methods Randomised controlled trial.
Participants 60 adult patients with acute leukaemia were randomly allocated to one of two groups:
• Liberal group: n = 31; M/F = 14/17; mean (sd) age = 45.3 (16.8) years
• Restrictive group: n = 29; M/F = 1811; mean (sd) age = 50.8 (15.3) years
Interventions • Liberal group were transfused two units of RBC when the Hb concentration fell
below 12.0g/dL.
• Restrictive group were transfused two units of RBC if the Hb concentration
dropped below 8.0g/dL, with a target range of 85-95g/dL.
Outcomes Outcomes reported: transfusions, bleeding risk.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated sequence generation.
Allocation concealment? Yes Internet-based, central allocation.
Blinding?
All outcomes
Unclear “Single-blinded” - blind outcome assessment.
Incomplete outcome data addressed?
All outcomes
Yes No missing data.
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Zygun 2009
Methods Randomised controlled trial.
Participants 30 patients with severe traumatic brain injury were randomly allocated to one of three
groups:
• Liberal group 1: n = 10
• Liberal group 2: n = 10
• Restrictive group: n = 10
NB: Mean (sd) age = 39 (15) years, 70% of trial subjects were male
Interventions • Liberal group 1 were transfused two units of RBC when the Hb concentration fell
below 9.0g/dL.
• Liberal group 2 were transfused two units of RBC when the Hb concentration fell
below 10.0g/dL.
• Restrictive group were transfused two units of RBC if the Hb concentration
dropped below 8.0g/dL
Outcomes Outcomes reported: change in brain tissue oxygen, brain pH, mortality.
Notes Additional data were obtained from lead trialist for inclusion in the meta-analysis. Data
from liberal groups 1 and 2 combined for analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer random number generator.
Allocation concealment? Unclear No information.
Blinding?
All outcomes
Unclear No information.
Incomplete outcome data addressed?
All outcomes
Yes No missing data.
Hb = Haemoglobin
Hct = Haematocrit
PCWP = Pulmonary capillary wedge pressure
RBC = Red Blood Cells
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Vichinsky 1995 Intervention not relevant.
Characteristics of ongoing studies [ordered by study ID]
FOCUS
Trial name or title The Transfusion Trial doe Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture
Repair (FOCUS)
Methods Randomised, unblinded, parallel, two-group multi-centre trial
Participants Patients 50 years or older, who are undergoing surgical repair of a hip fracture, with Hb concentrations
below 10.0g/dL within three days after surgery and who have clinical evidence for cardiovascular disease or
cardiovascular risk factors
Sample size = 2016
Interventions • Liberal group - receive packed RBC when haemoglobin level dropped below 10.0g/dL.
• Restrictive (’symptomatic strategy’) group - receive transfusion if develop symptoms of anaemia or if
Hb falls below 8.0g/dL
Outcomes Primary outcome is inability to walk 10 feet (or across a room) without human assistance or death prior
to closure of the window for the 60-day, 30 and 60 day mortality. Other outcomes are Hb concentration,
acute coronary syndrome (ACS), in-hospital myocardial infarction, unstable angina, or death, disposition
on discharge, survival, functional measures, falls, fatigue, pain, readmission to hospital, and self-efficacy,
pneumonia, wound infection, thromboembolism, stroke or transient ischaemic attack
Starting date August 10, 2004
Contact information Jeffrey Carson (carson@umdnj.edu)
Notes
MINT
Trial name or title Myocardial Ischemia and Transfusion
Methods Randomised, single-blinded, parallel trial
Participants Anaemic patients with acute coronary syndrome, aged 18 years or over
Estimated sample size = 200
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MINT (Continued)
Interventions • Liberal group - receive one unit of packed RBC following randomisation and received enough blood to
raise Hb concentration above 10g/dL, during hospitalisation for up to 30 days.
• Restrictive group - receive transfusion if develop symptoms of anaemia or if Hb falls below 8.0g/dL.
Outcomes Trial performance and feasibility, Hb concentration, mortality or myocardial ischaemia, unscheduled hospital
admission, stroke, congestive hear failure, stent thrombosis, deep vein thrombosis, pulmonary embolism,
pneumonia, blood stream infection
Starting date September 2009
Contact information Jeffrey Carson (carson@umdnj.edu)
Notes
TITRe 2
Trial name or title A multi-centre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion
rates, morbidity and healthcare resources use following cardiac surgery
Methods Multicentre randomised controlled trial.
Participants Patients aged 16 year and over undergoing cardiac surgery.
Interventions • Liberal group - receive packed RBC if Hb concentration falls below 9g/dL, objective is to maintain Hb
above 9g/dL.
• Restrictive group - receive packed RBC if Hb concentration falls below 7.5g/dL, objective is to
maintain Hb above 7.5g/dL.
Outcomes Infectious events, ischaemic events, units of RBC transfused, duration of hospital stay, all-cause mortality,
resource use
Starting date December 2008
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Blood transfusions
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Patients exposed to blood
transfusion (all studies)
15 3607 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.54, 0.74]
2 Patients exposed to allogeneic
blood transfusion
8 1628 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.51, 0.76]
3 Patients exposed to autologous
blood transfusion
2 165 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.12, 1.82]
4 Patients exposed to blood
transfusion (by clinical setting)
15 3607 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.54, 0.74]
4.1 Cardiac surgery 2 466 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.88]
4.2 Orthopaedic surgery 5 1152 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.35, 0.85]
4.3 Vascular 1 99 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.77, 1.08]
4.4 Acute blood loss/trauma 3 286 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.30, 0.89]
4.5 Cancer 1 60 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.82, 1.12]
4.6 Critical care 3 1544 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.42, 0.75]
5 Patients exposed to blood
transfusion (by transfusion
threshold)
10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Difference ≥2g/dL 8 2240 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.52, 0.76]
5.2 Difference <2g/dL 2 527 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.63, 1.07]
6 Patients exposed to blood
transfusion (by allocation
concealment)
15 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Low risk of bias 3 781 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.33, 1.09]
6.2 Unclear risk of bias 10 2360 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.53, 0.75]
6.3 High risk of bias 2 466 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.62, 0.88]
7 Units of blood transfused 8 2715 Mean Difference (IV, Random, 95% CI) -1.19 [-1.85, -0.53]
8 Units of blood transfused in
those transfused
8 1555 Mean Difference (IV, Random, 95% CI) -0.75 [-1.30, -0.20]
Comparison 2. Haematocrit levels
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Haematocrit levels - restrictive
versus liberal
9 2574 Mean Difference (IV, Random, 95% CI) -4.69 [-6.71, -2.67]
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Comparison 3. Mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ≤14-day mortality 2 821 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.06, 2.96]
2 30-day mortality 9 2461 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.66, 1.05]
3 60-day mortality 2 922 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.46, 2.60]
4 120-day mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5 Hospital mortality 4 1409 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.98]
6 ICU mortality 3 736 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.59, 2.23]
7 Mortality (unspecified follow-up
period)
1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 4. Length of stay
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hospital length of stay 7 2210 Mean Difference (IV, Random, 95% CI) -0.39 [-0.91, 0.13]
2 ICU length of stay 4 1612 Mean Difference (IV, Random, 95% CI) -0.32 [-1.09, 0.44]
Comparison 5. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cardiac events 5 1530 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.57, 1.00]
2 Myocardial infarction 7 1868 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.21, 1.21]
3 Pulmonary oedema 4 1633 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.18, 1.31]
4 Cerebrovascular accident (CVA)
- stroke
3 242 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.17, 5.52]
5 Pneumonia 4 1679 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.78, 1.29]
6 Thromboembolism 2 204 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.14, 6.36]
7 Rebleeding 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8 Infection 4 1788 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.60, 0.97]
9 Renal failure 2 1065 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.66, 5.22]
10 Mental confusion 2 247 Risk Ratio (M-H, Random, 95% CI) 1.86 [0.63, 5.44]
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Analysis 1.1. Comparison 1 Blood transfusions, Outcome 1 Patients exposed to blood transfusion (all
studies).
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 1 Patients exposed to blood transfusion (all studies)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blair 1986 5/26 24/24 2.9 % 0.21 [ 0.10, 0.44 ]
Bracey 1999 74/212 104/216 7.3 % 0.72 [ 0.58, 0.91 ]
Bush 1997 40/50 43/49 7.8 % 0.91 [ 0.77, 1.08 ]
Carson 1998 19/42 41/42 6.1 % 0.46 [ 0.33, 0.65 ]
Colomo 2008 68/109 95/105 7.9 % 0.69 [ 0.59, 0.81 ]
Foss 2009 22/60 44/60 5.8 % 0.50 [ 0.35, 0.72 ]
Grover 2005 37/109 46/109 6.1 % 0.80 [ 0.57, 1.13 ]
Hebert 1995 18/33 35/36 6.4 % 0.56 [ 0.41, 0.77 ]
Hebert 1999 280/418 420/420 8.5 % 0.67 [ 0.63, 0.72 ]
Johnson 1992 15/20 18/18 6.9 % 0.76 [ 0.58, 0.99 ]
Lacroix 2007 146/320 310/317 8.2 % 0.47 [ 0.41, 0.53 ]
Lotke 1999 16/62 65/65 5.3 % 0.26 [ 0.17, 0.40 ]
So-Osman 2010 109/299 119/304 7.5 % 0.93 [ 0.76, 1.14 ]
Topley 1956 8/12 10/10 5.3 % 0.68 [ 0.45, 1.04 ]
Webert 2008 26/29 29/31 8.0 % 0.96 [ 0.82, 1.12 ]
Total (95% CI) 1801 1806 100.0 % 0.63 [ 0.54, 0.74 ]
Total events: 883 (Restrictive), 1403 (Liberal)
Heterogeneity: Tau2 = 0.07; Chi2 = 123.82, df = 14 (P<0.00001); I2 =89%
Test for overall effect: Z = 5.79 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours Restrictive Favours Liberal
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Analysis 1.2. Comparison 1 Blood transfusions, Outcome 2 Patients exposed to allogeneic blood transfusion.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 2 Patients exposed to allogeneic blood transfusion
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blair 1986 5/26 24/24 5.2 % 0.21 [ 0.10, 0.44 ]
Bracey 1999 74/212 104/216 16.7 % 0.72 [ 0.58, 0.91 ]
Bush 1997 40/50 43/49 18.5 % 0.91 [ 0.77, 1.08 ]
Carson 1998 19/42 41/42 13.2 % 0.46 [ 0.33, 0.65 ]
Hebert 1995 18/33 35/36 13.8 % 0.56 [ 0.41, 0.77 ]
Hebert 1999 280/418 420/420 21.1 % 0.67 [ 0.63, 0.72 ]
Johnson 1992 0/20 3/18 0.4 % 0.13 [ 0.01, 2.34 ]
Topley 1956 8/12 10/10 11.0 % 0.68 [ 0.45, 1.04 ]
Total (95% CI) 813 815 100.0 % 0.63 [ 0.51, 0.76 ]
Total events: 444 (Restrictive), 680 (Liberal)
Heterogeneity: Tau2 = 0.05; Chi2 = 30.26, df = 7 (P = 0.00008); I2 =77%
Test for overall effect: Z = 4.69 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours Restrictive Favours Liberal
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Analysis 1.3. Comparison 1 Blood transfusions, Outcome 3 Patients exposed to autologous blood
transfusion.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 3 Patients exposed to autologous blood transfusion
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Johnson 1992 15/20 17/18 50.6 % 0.79 [ 0.60, 1.05 ]
Lotke 1999 16/62 65/65 49.4 % 0.26 [ 0.17, 0.40 ]
Total (95% CI) 82 83 100.0 % 0.46 [ 0.12, 1.82 ]
Total events: 31 (Restrictive), 82 (Liberal)
Heterogeneity: Tau2 = 0.95; Chi2 = 30.25, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.11 (P = 0.27)
0.02 0.1 1 10 50
Favours Restrictive Favours Liberal
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Analysis 1.4. Comparison 1 Blood transfusions, Outcome 4 Patients exposed to blood transfusion (by
clinical setting).
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 4 Patients exposed to blood transfusion (by clinical setting)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Bracey 1999 74/212 104/216 7.3 % 0.72 [ 0.58, 0.91 ]
Johnson 1992 15/20 18/18 6.9 % 0.76 [ 0.58, 0.99 ]
Subtotal (95% CI) 232 234 14.2 % 0.74 [ 0.62, 0.88 ]
Total events: 89 (Restrictive), 122 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00065)
2 Orthopaedic surgery
Carson 1998 19/42 41/42 6.1 % 0.46 [ 0.33, 0.65 ]
Foss 2009 22/60 44/60 5.8 % 0.50 [ 0.35, 0.72 ]
Grover 2005 37/109 46/109 6.1 % 0.80 [ 0.57, 1.13 ]
Lotke 1999 16/62 65/65 5.3 % 0.26 [ 0.17, 0.40 ]
So-Osman 2010 109/299 119/304 7.5 % 0.93 [ 0.76, 1.14 ]
Subtotal (95% CI) 572 580 30.9 % 0.55 [ 0.35, 0.85 ]
Total events: 203 (Restrictive), 315 (Liberal)
Heterogeneity: Tau2 = 0.22; Chi2 = 37.29, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.69 (P = 0.0071)
3 Vascular
Bush 1997 40/50 43/49 7.8 % 0.91 [ 0.77, 1.08 ]
Subtotal (95% CI) 50 49 7.8 % 0.91 [ 0.77, 1.08 ]
Total events: 40 (Restrictive), 43 (Liberal)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
4 Acute blood loss/trauma
Blair 1986 5/26 24/24 2.9 % 0.21 [ 0.10, 0.44 ]
Colomo 2008 68/109 95/105 7.9 % 0.69 [ 0.59, 0.81 ]
Topley 1956 8/12 10/10 5.3 % 0.68 [ 0.45, 1.04 ]
Subtotal (95% CI) 147 139 16.1 % 0.52 [ 0.30, 0.89 ]
Total events: 81 (Restrictive), 129 (Liberal)
Heterogeneity: Tau2 = 0.18; Chi2 = 11.22, df = 2 (P = 0.004); I2 =82%
0.1 0.2 0.5 1 2 5 10
Favours Restrictive Favours Liberal
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(. . . Continued)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.36 (P = 0.018)
5 Cancer
Webert 2008 26/29 29/31 8.0 % 0.96 [ 0.82, 1.12 ]
Subtotal (95% CI) 29 31 8.0 % 0.96 [ 0.82, 1.12 ]
Total events: 26 (Restrictive), 29 (Liberal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
6 Critical care
Hebert 1995 18/33 35/36 6.4 % 0.56 [ 0.41, 0.77 ]
Hebert 1999 280/418 420/420 8.5 % 0.67 [ 0.63, 0.72 ]
Lacroix 2007 146/320 310/317 8.2 % 0.47 [ 0.41, 0.53 ]
Subtotal (95% CI) 771 773 23.1 % 0.56 [ 0.42, 0.75 ]
Total events: 444 (Restrictive), 765 (Liberal)
Heterogeneity: Tau2 = 0.06; Chi2 = 29.71, df = 2 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.82 (P = 0.00013)
Total (95% CI) 1801 1806 100.0 % 0.63 [ 0.54, 0.74 ]
Total events: 883 (Restrictive), 1403 (Liberal)
Heterogeneity: Tau2 = 0.07; Chi2 = 123.82, df = 14 (P<0.00001); I2 =89%
Test for overall effect: Z = 5.79 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 5 (P = 0.0), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours Restrictive Favours Liberal
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Analysis 1.5. Comparison 1 Blood transfusions, Outcome 5 Patients exposed to blood transfusion (by
transfusion threshold).
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 5 Patients exposed to blood transfusion (by transfusion threshold)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Difference ≥2g/dL
Carson 1998 19/42 41/42 10.5 % 0.46 [ 0.33, 0.65 ]
Colomo 2008 68/109 95/105 14.1 % 0.69 [ 0.59, 0.81 ]
Foss 2009 22/60 44/60 9.9 % 0.50 [ 0.35, 0.72 ]
Grover 2005 37/109 46/109 10.4 % 0.80 [ 0.57, 1.13 ]
Hebert 1995 18/33 35/36 10.9 % 0.56 [ 0.41, 0.77 ]
Hebert 1999 280/418 420/420 15.3 % 0.67 [ 0.63, 0.72 ]
Lacroix 2007 146/320 310/317 14.7 % 0.47 [ 0.41, 0.53 ]
Webert 2008 26/29 29/31 14.1 % 0.96 [ 0.82, 1.12 ]
Subtotal (95% CI) 1120 1120 100.0 % 0.63 [ 0.52, 0.76 ]
Total events: 616 (Restrictive), 1020 (Liberal)
Heterogeneity: Tau2 = 0.06; Chi2 = 69.88, df = 7 (P<0.00001); I2 =90%
Test for overall effect: Z = 4.77 (P < 0.00001)
2 Difference <2g/dL
Bracey 1999 74/212 104/216 46.1 % 0.72 [ 0.58, 0.91 ]
Bush 1997 40/50 43/49 53.9 % 0.91 [ 0.77, 1.08 ]
Subtotal (95% CI) 262 265 100.0 % 0.82 [ 0.63, 1.07 ]
Total events: 114 (Restrictive), 147 (Liberal)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.48, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.45 (P = 0.15)
0.5 0.7 1 1.5 2
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Analysis 1.6. Comparison 1 Blood transfusions, Outcome 6 Patients exposed to blood transfusion (by
allocation concealment).
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 6 Patients exposed to blood transfusion (by allocation concealment)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Low risk of bias
Carson 1998 19/42 41/42 31.5 % 0.46 [ 0.33, 0.65 ]
Lacroix 2007 146/320 310/317 34.4 % 0.47 [ 0.41, 0.53 ]
Webert 2008 26/29 29/31 34.1 % 0.96 [ 0.82, 1.12 ]
Subtotal (95% CI) 391 390 100.0 % 0.60 [ 0.33, 1.09 ]
Total events: 191 (Restrictive), 380 (Liberal)
Heterogeneity: Tau2 = 0.27; Chi2 = 68.89, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Unclear risk of bias
Blair 1986 5/26 24/24 4.1 % 0.21 [ 0.10, 0.44 ]
Bush 1997 40/50 43/49 12.6 % 0.91 [ 0.77, 1.08 ]
Colomo 2008 68/109 95/105 12.9 % 0.69 [ 0.59, 0.81 ]
Foss 2009 22/60 44/60 8.9 % 0.50 [ 0.35, 0.72 ]
Grover 2005 37/109 46/109 9.4 % 0.80 [ 0.57, 1.13 ]
Hebert 1995 18/33 35/36 9.9 % 0.56 [ 0.41, 0.77 ]
Hebert 1999 280/418 420/420 14.1 % 0.67 [ 0.63, 0.72 ]
Lotke 1999 16/62 65/65 8.1 % 0.26 [ 0.17, 0.40 ]
So-Osman 2010 109/299 119/304 12.1 % 0.93 [ 0.76, 1.14 ]
Topley 1956 8/12 10/10 8.0 % 0.68 [ 0.45, 1.04 ]
Subtotal (95% CI) 1178 1182 100.0 % 0.63 [ 0.53, 0.75 ]
Total events: 603 (Restrictive), 901 (Liberal)
Heterogeneity: Tau2 = 0.06; Chi2 = 55.56, df = 9 (P<0.00001); I2 =84%
Test for overall effect: Z = 5.12 (P < 0.00001)
3 High risk of bias
Bracey 1999 74/212 104/216 57.1 % 0.72 [ 0.58, 0.91 ]
Johnson 1992 15/20 18/18 42.9 % 0.76 [ 0.58, 0.99 ]
Subtotal (95% CI) 232 234 100.0 % 0.74 [ 0.62, 0.88 ]
Total events: 89 (Restrictive), 122 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00065)
0.1 0.2 0.5 1 2 5 10
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Analysis 1.7. Comparison 1 Blood transfusions, Outcome 7 Units of blood transfused.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 7 Units of blood transfused
Study or subgroup Restrictive Liberal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blair 1986 26 2.6 (3) 24 4.6 (1.5) 10.2 % -2.00 [ -3.30, -0.70 ]
Bracey 1999 212 0.9 (1.5) 216 1.4 (1.8) 16.3 % -0.50 [ -0.81, -0.19 ]
Bush 1997 50 2.8 (3.1) 49 3.7 (3.5) 10.2 % -0.90 [ -2.20, 0.40 ]
Hebert 1999 418 2.6 (4.1) 420 5.6 (5.3) 14.6 % -3.00 [ -3.64, -2.36 ]
Johnson 1992 20 1 (0.86) 18 2.05 (0.93) 15.0 % -1.05 [ -1.62, -0.48 ]
Lacroix 2007 320 0.9 (2.6) 317 1.7 (2.2) 16.0 % -0.80 [ -1.17, -0.43 ]
So-Osman 2010 299 0.78 (1.4) 304 0.86 (1.6) 16.5 % -0.08 [ -0.32, 0.16 ]
Topley 1956 12 4.8 (6.7) 10 11.3 (6.9) 1.2 % -6.50 [ -12.21, -0.79 ]
Total (95% CI) 1357 1358 100.0 % -1.19 [ -1.85, -0.53 ]
Heterogeneity: Tau2 = 0.67; Chi2 = 84.46, df = 7 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.54 (P = 0.00040)
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Analysis 1.8. Comparison 1 Blood transfusions, Outcome 8 Units of blood transfused in those transfused.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 1 Blood transfusions
Outcome: 8 Units of blood transfused in those transfused
Study or subgroup Restrictive Liberal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blair 1986 5 2.6 (1.34) 24 4.6 (1.47) 9.4 % -2.00 [ -3.31, -0.69 ]
Bracey 1999 74 2.58 (1.45) 104 2.91 (1.53) 17.7 % -0.33 [ -0.77, 0.11 ]
Bush 1997 40 3.5 (3.09) 43 4.22 (3.43) 8.7 % -0.72 [ -2.12, 0.68 ]
Carson 1998 19 1.84 (1.12) 39 2 (0.89) 16.4 % -0.16 [ -0.74, 0.42 ]
Hebert 1999 280 3.88 (4.49) 420 5.6 (5.3) 14.8 % -1.72 [ -2.45, -0.99 ]
Johnson 1992 15 1 (0.86) 18 2.05 (0.93) 16.1 % -1.05 [ -1.66, -0.44 ]
Lacroix 2007 146 1.9 (3.4) 310 1.7 (2.1) 16.2 % 0.20 [ -0.40, 0.80 ]
Topley 1956 8 7.2 (7.13) 10 11.34 (6.87) 0.7 % -4.14 [ -10.66, 2.38 ]
Total (95% CI) 587 968 100.0 % -0.75 [ -1.30, -0.20 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 27.05, df = 7 (P = 0.00033); I2 =74%
Test for overall effect: Z = 2.69 (P = 0.0072)
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Analysis 2.1. Comparison 2 Haematocrit levels, Outcome 1 Haematocrit levels - restrictive versus liberal.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 2 Haematocrit levels
Outcome: 1 Haematocrit levels - restrictive versus liberal
Study or subgroup Restrictive Liberal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blair 1986 26 37 (7.1) 24 37 (7.8) 8.1 % 0.0 [ -4.15, 4.15 ]
Bush 1997 50 29.4 (3.9) 49 33 (3.6) 11.5 % -3.60 [ -5.08, -2.12 ]
Carson 1998 42 29.1 (2.7) 42 32.1 (2.7) 11.8 % -3.00 [ -4.15, -1.85 ]
Fortune 1987 12 30.3 (2.07) 13 38.1 (2.16) 11.4 % -7.80 [ -9.46, -6.14 ]
Grover 2005 109 29.4 (3.69) 107 33.3 (2.79) 12.0 % -3.90 [ -4.77, -3.03 ]
Hebert 1999 418 25.5 (2.1) 420 32.1 (2.1) 12.3 % -6.60 [ -6.88, -6.32 ]
Lacroix 2007 320 28.2 (3.6) 317 33.6 (3.3) 12.2 % -5.40 [ -5.94, -4.86 ]
So-Osman 2010 299 34.2 (3.3) 304 34.2 (3.9) 12.2 % 0.0 [ -0.58, 0.58 ]
Topley 1956 12 33.75 (2.15) 10 46.68 (5.97) 8.4 % -12.93 [ -16.83, -9.03 ]
Total (95% CI) 1288 1286 100.0 % -4.69 [ -6.71, -2.67 ]
Heterogeneity: Tau2 = 8.61; Chi2 = 463.96, df = 8 (P<0.00001); I2 =98%
Test for overall effect: Z = 4.55 (P < 0.00001)
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Analysis 3.1. Comparison 3 Mortality, Outcome 1 ≤14-day mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 1 ≤14-day mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Grover 2005 0/109 1/109 36.1 % 0.33 [ 0.01, 8.09 ]
So-Osman 2010 1/299 2/304 63.9 % 0.51 [ 0.05, 5.58 ]
Total (95% CI) 408 413 100.0 % 0.44 [ 0.06, 2.96 ]
Total events: 1 (Restrictive), 3 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Mortality, Outcome 2 30-day mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 2 30-day mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blair 1986 0/26 2/24 0.6 % 0.19 [ 0.01, 3.67 ]
Bracey 1999 3/215 6/222 2.8 % 0.52 [ 0.13, 2.04 ]
Bush 1997 4/50 4/49 3.0 % 0.98 [ 0.26, 3.70 ]
Carson 1998 1/42 1/42 0.7 % 1.00 [ 0.06, 15.47 ]
Foss 2009 5/60 0/60 0.6 % 11.00 [ 0.62, 194.63 ]
Hebert 1995 8/33 9/36 7.7 % 0.97 [ 0.42, 2.22 ]
Hebert 1999 78/418 98/420 74.7 % 0.80 [ 0.61, 1.04 ]
Lacroix 2007 14/320 14/317 10.0 % 0.99 [ 0.48, 2.04 ]
Lotke 1999 0/62 0/65 Not estimable
Total (95% CI) 1226 1235 100.0 % 0.83 [ 0.66, 1.05 ]
Total events: 113 (Restrictive), 134 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.09, df = 7 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 3.3. Comparison 3 Mortality, Outcome 3 60-day mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 3 60-day mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carson 1998 5/42 2/42 22.1 % 2.50 [ 0.51, 12.17 ]
Hebert 1999 95/418 111/420 77.9 % 0.86 [ 0.68, 1.09 ]
Total (95% CI) 460 462 100.0 % 1.09 [ 0.46, 2.60 ]
Total events: 100 (Restrictive), 113 (Liberal)
Heterogeneity: Tau2 = 0.24; Chi2 = 1.71, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 0.19 (P = 0.85)
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Analysis 3.4. Comparison 3 Mortality, Outcome 4 120-day mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 4 120-day mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hebert 1995 13/33 11/36 1.29 [ 0.67, 2.47 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 13 (Restrictive), 11 (Liberal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
0.2 0.5 1 2 5
Favours Restrictive Favours Liberal
46Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.5. Comparison 3 Mortality, Outcome 5 Hospital mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 5 Hospital mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blair 1986 0/26 2/24 0.6 % 0.19 [ 0.01, 3.67 ]
Bracey 1999 3/215 6/222 2.8 % 0.52 [ 0.13, 2.04 ]
Carson 1998 0/42 0/42 Not estimable
Hebert 1999 93/418 118/420 96.6 % 0.79 [ 0.63, 1.00 ]
Total (95% CI) 701 708 100.0 % 0.78 [ 0.62, 0.98 ]
Total events: 96 (Restrictive), 126 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.15 (P = 0.031)
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Analysis 3.6. Comparison 3 Mortality, Outcome 6 ICU mortality.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 6 ICU mortality
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hebert 1995 5/33 7/36 40.1 % 0.78 [ 0.27, 2.22 ]
Lacroix 2007 11/320 8/317 54.5 % 1.36 [ 0.56, 3.34 ]
Zygun 2009 3/20 0/10 5.3 % 3.67 [ 0.21, 64.80 ]
Total (95% CI) 373 363 100.0 % 1.15 [ 0.59, 2.23 ]
Total events: 19 (Restrictive), 15 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.32, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 3.7. Comparison 3 Mortality, Outcome 7 Mortality (unspecified follow-up period).
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 3 Mortality
Outcome: 7 Mortality (unspecified follow-up period)
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Colomo 2008 12/109 17/105 0.68 [ 0.34, 1.35 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 12 (Restrictive), 17 (Liberal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 4.1. Comparison 4 Length of stay, Outcome 1 Hospital length of stay.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 4 Length of stay
Outcome: 1 Hospital length of stay
Study or subgroup Restrictive Liberal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bracey 1999 212 7.5 (2.9) 216 7.9 (4.9) 46.5 % -0.40 [ -1.16, 0.36 ]
Bush 1997 50 10 (6) 49 11 (9) 3.0 % -1.00 [ -4.02, 2.02 ]
Carson 1998 42 6.4 (3.4) 42 6.3 (3.4) 12.7 % 0.10 [ -1.35, 1.55 ]
Foss 2009 60 17 (12.9) 60 18.4 (14.4) 1.1 % -1.40 [ -6.29, 3.49 ]
Hebert 1999 418 34.8 (19.5) 420 35.5 (19.4) 3.9 % -0.70 [ -3.33, 1.93 ]
Johnson 1992 20 7.9 (4.3) 18 7.6 (1.9) 6.2 % 0.30 [ -1.78, 2.38 ]
So-Osman 2010 299 9.6 (5) 304 10.2 (7.4) 26.6 % -0.60 [ -1.61, 0.41 ]
Total (95% CI) 1101 1109 100.0 % -0.39 [ -0.91, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 4.2. Comparison 4 Length of stay, Outcome 2 ICU length of stay.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 4 Length of stay
Outcome: 2 ICU length of stay
Study or subgroup Restrictive Liberal
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bush 1997 50 4 (4) 49 4 (8) 9.4 % 0.0 [ -2.50, 2.50 ]
Hebert 1999 418 11 (10.7) 420 11.5 (11.3) 26.4 % -0.50 [ -1.99, 0.99 ]
Johnson 1992 20 3.2 (0.7) 18 3.3 (3.4) 22.8 % -0.10 [ -1.70, 1.50 ]
Lacroix 2007 320 9.5 (7.9) 317 9.9 (7.4) 41.4 % -0.40 [ -1.59, 0.79 ]
Total (95% CI) 808 804 100.0 % -0.32 [ -1.09, 0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 5.1. Comparison 5 Adverse events, Outcome 1 Cardiac events.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 1 Cardiac events
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bracey 1999 44/212 49/216 38.0 % 0.91 [ 0.64, 1.31 ]
Bush 1997 8/50 8/49 8.8 % 0.98 [ 0.40, 2.40 ]
Hebert 1999 55/418 88/420 45.9 % 0.63 [ 0.46, 0.85 ]
Johnson 1992 4/20 7/18 6.5 % 0.51 [ 0.18, 1.47 ]
Lotke 1999 2/62 0/65 0.8 % 5.24 [ 0.26, 106.98 ]
Total (95% CI) 762 768 100.0 % 0.76 [ 0.57, 1.00 ]
Total events: 113 (Restrictive), 152 (Liberal)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.87, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 1.97 (P = 0.049)
0.1 0.2 0.5 1 2 5 10
Favours Restrictive Favours Liberal
51Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.2. Comparison 5 Adverse events, Outcome 2 Myocardial infarction.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 2 Myocardial infarction
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bracey 1999 1/212 0/216 7.5 % 3.06 [ 0.13, 74.61 ]
Bush 1997 1/50 2/49 13.7 % 0.49 [ 0.05, 5.23 ]
Foss 2009 1/60 0/60 7.6 % 3.00 [ 0.12, 72.20 ]
Grover 2005 0/109 1/109 7.5 % 0.33 [ 0.01, 8.09 ]
Hebert 1999 3/418 12/420 48.4 % 0.25 [ 0.07, 0.88 ]
Johnson 1992 0/20 1/18 7.8 % 0.30 [ 0.01, 6.97 ]
Lotke 1999 1/62 0/65 7.6 % 3.14 [ 0.13, 75.72 ]
Total (95% CI) 931 937 100.0 % 0.50 [ 0.21, 1.21 ]
Total events: 7 (Restrictive), 16 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.05, df = 6 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 5.3. Comparison 5 Adverse events, Outcome 3 Pulmonary oedema.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 3 Pulmonary oedema
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Foss 2009 2/60 0/60 9.4 % 5.00 [ 0.25, 102.00 ]
Hebert 1999 22/418 45/420 71.6 % 0.49 [ 0.30, 0.80 ]
Johnson 1992 0/20 1/18 8.8 % 0.30 [ 0.01, 6.97 ]
Lacroix 2007 0/320 5/317 10.2 % 0.09 [ 0.01, 1.62 ]
Total (95% CI) 818 815 100.0 % 0.49 [ 0.18, 1.31 ]
Total events: 24 (Restrictive), 51 (Liberal)
Heterogeneity: Tau2 = 0.29; Chi2 = 3.69, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 5.4. Comparison 5 Adverse events, Outcome 4 Cerebrovascular accident (CVA) - stroke.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 4 Cerebrovascular accident (CVA) - stroke
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carson 1998 0/42 1/42 29.8 % 0.33 [ 0.01, 7.96 ]
Foss 2009 1/60 1/60 39.7 % 1.00 [ 0.06, 15.62 ]
Johnson 1992 1/20 0/18 30.4 % 2.71 [ 0.12, 62.70 ]
Total (95% CI) 122 120 100.0 % 0.98 [ 0.17, 5.52 ]
Total events: 2 (Restrictive), 2 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
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Analysis 5.5. Comparison 5 Adverse events, Outcome 5 Pneumonia.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 5 Pneumonia
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carson 1998 0/42 2/42 0.7 % 0.20 [ 0.01, 4.04 ]
Foss 2009 1/60 2/60 1.1 % 0.50 [ 0.05, 5.37 ]
Hebert 1999 87/418 86/420 89.3 % 1.02 [ 0.78, 1.33 ]
Lacroix 2007 11/320 10/317 8.9 % 1.09 [ 0.47, 2.53 ]
Total (95% CI) 840 839 100.0 % 1.00 [ 0.78, 1.29 ]
Total events: 99 (Restrictive), 100 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.49, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
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Analysis 5.6. Comparison 5 Adverse events, Outcome 6 Thromboembolism.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 6 Thromboembolism
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carson 1998 1/42 0/42 35.9 % 3.00 [ 0.13, 71.61 ]
Foss 2009 1/60 2/60 64.1 % 0.50 [ 0.05, 5.37 ]
Total (95% CI) 102 102 100.0 % 0.95 [ 0.14, 6.36 ]
Total events: 2 (Restrictive), 2 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 5.7. Comparison 5 Adverse events, Outcome 7 Rebleeding.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 7 Rebleeding
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Blair 1986 1/26 9/24 0.10 [ 0.01, 0.75 ]
Subtotal (95% CI) 0 0 0.0 [ 0.0, 0.0 ]
Total events: 1 (Restrictive), 9 (Liberal)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 5.8. Comparison 5 Adverse events, Outcome 8 Infection.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 8 Infection
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bracey 1999 5/212 3/216 3.0 % 1.70 [ 0.41, 7.02 ]
Foss 2009 6/60 11/60 6.9 % 0.55 [ 0.22, 1.38 ]
Lacroix 2007 65/320 79/317 71.1 % 0.82 [ 0.61, 1.09 ]
So-Osman 2010 18/299 31/304 19.1 % 0.59 [ 0.34, 1.03 ]
Total (95% CI) 891 897 100.0 % 0.76 [ 0.60, 0.97 ]
Total events: 94 (Restrictive), 124 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.74, df = 3 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
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Analysis 5.9. Comparison 5 Adverse events, Outcome 9 Renal failure.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 9 Renal failure
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bracey 1999 8/212 5/216 88.3 % 1.63 [ 0.54, 4.90 ]
Lacroix 2007 2/320 0/317 11.7 % 4.95 [ 0.24, 102.77 ]
Total (95% CI) 532 533 100.0 % 1.86 [ 0.66, 5.22 ]
Total events: 10 (Restrictive), 5 (Liberal)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 5.10. Comparison 5 Adverse events, Outcome 10 Mental confusion.
Review: Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion
Comparison: 5 Adverse events
Outcome: 10 Mental confusion
Study or subgroup Restrictive Liberal Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Foss 2009 6/60 5/60 61.0 % 1.20 [ 0.39, 3.72 ]
Lotke 1999 7/62 2/65 39.0 % 3.67 [ 0.79, 16.99 ]
Total (95% CI) 122 125 100.0 % 1.86 [ 0.63, 5.44 ]
Total events: 13 (Restrictive), 7 (Liberal)
Heterogeneity: Tau2 = 0.16; Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.13 (P = 0.26)
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A P P E N D I C E S
Appendix 1. Search strategy
CENTRAL (the Cochrane Library 2009, Issue 3): 138 records
#1 MeSH descriptor Blood Transfusion, this term only with qualifiers: MT,ST
#2 transfus* near5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or standard*)
#3 (Red blood cell* or RBC) near5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or
standard*) and (therap* or transfus*)
#4 (H?emoglobin or h?emocrit or HB or HCT) near5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg*
or criteri* or standard*)
#5 transfus* near5 (restrict* or liberal*)
#6 (blood transfus*) near3 (management or program*)
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6) (from 2004 to 2009)
Ovid MEDLINE(R) 1950 to August Week 2 2009: 505 records
1. *Blood Transfusion/
2. ((Red blood cell* or RBC) adj3 (therap* or transfus*)).mp.
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3. 1 or 2
4. exp Reference Standards/
5. standards.fs.
6. methods.fs.
7. 4 or 5 or 6
8. 3 and 7
9. (transfus* adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or standard*)).mp.
10. ((Red blood cell* or RBC) adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or
standard*)).mp.
11. ((H?emoglobin or h?emocrit or HB or HCT) adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg*
or criteri* or standard*)).mp.
12. (transfus* adj5 (restrict* or liberal*)).mp.
13. ((blood or transfus*) adj3 (management or program*)).mp.
14. 8 or 9 or 10 or 11 or 12 or 13
15. randomi?ed.ab,ti.
16. randomized controlled trial.pt.
17. controlled clinical trial.pt.
18. placebo.ab.
19. clinical trials as topic.sh.
20. randomly.ab.
21. trial.ti.
22. 15 or 16 or 17 or 18 or 19 or 20 or 21
23. (animals not (humans and animals)).sh.
24. 22 not 23
25. 24 and 14
26. (2004* or 2005* or 2006* or 2007* or 2008* or 2009*).em.
27. 26 and 25
EMBASE 1980 to 2009 Week 33: 572 records
1. *Blood Transfusion/
2. ((Red blood cell* or RBC) adj3 (therap* or transfus*)).mp.
3. (transfus* adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or standard*)).mp.
4. ((Red blood cell* or RBC) adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg* or criteri* or
standard*)).mp.
5. ((H?emoglobin or h?emocrit or HB or HCT) adj5 (polic*or practic* or protocol* or trigger* or threshold*or indicator* or strateg*
or criteri* or standard*)).mp.
6. (transfus* adj5 (restrict* or liberal*)).mp.
7. ((blood or transfus*) adj3 (management or program*)).mp.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Randomized Controlled Trial/
10. exp controlled clinical trial/
11. randomi?ed.ab,ti.
12. placebo.ab.
13. *Clinical Trial/
14. randomly.ab.
15. trial.ti.
16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp animal/ not (exp human/ and exp animal/)
18. 16 not 17
19. 8 and 18
20. (2004* or 2005* or 2006* or 2007* or 2008* or 2009*).em.
21. 19 and 20
ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) 2004 to August 2009
ISI Web of Science: Conference Proceedings Citation Index- Science (CPCI-S) 2004 to August 2009: 214 records
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#1 Topic=(Blood or “Red blood cell” or “Red blood cells” or RBC or Hemoglobin* or haemoglobin* or haemocrit or hemocrit or
HB or HCT) AND Topic=(transfus*) AND Topic=(polic* or practice or protocol* or trigger* or threshold* or indicator* or strateg*
or criteri* or standard* or restrict* or liberal* or management or program*)
#2 Topic=(randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR randomly
allocated OR at random OR randomized controlled trial) OR Topic=(controlled clinical trial OR controlled trial OR clinical trial OR
placebo)
#3 Topic=((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*))
#4 #2 or #3
#5 Topic=(human*)
#6 #4 and #5
#7 #1 and #6
WH A T ’ S N E W
Last assessed as up-to-date: 31 July 2009.
Date Event Description
12 February 2010 New citation required but conclusions have not
changed
The searches were updated to August 2009, seven new
trials have been included and the Results amended ac-
cordingly. The Background section of the review has
been updated. The overall conclusions of the review
remain unchanged
As part of this update the assessment of methodolog-
ical quality used in earlier versions of this review has
been replaced with an assessment of the risk of bias.
This amendment is in accordance to a change in the
Cochrane Collaboration’s methodological guidance
H I S T O R Y
Protocol first published: Issue 2, 2000
Review first published: Issue 2, 2002
Date Event Description
9 September 2008 Amended Converted to new review format.
17 November 2004 New search has been performed An updated search for new trials was conducted in November 2004. No
new trials for inclusion were identified
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C O N T R I B U T I O N S O F A U T H O R S
Contributors (names are listed alphabetically):
Paul Carless (University of Newcastle) performed computer database literature searches, screened abstracts and titles for relevant articles,
obtained relevant papers, applied inclusion/exclusion criteria to retrieved papers, extracted data from the trials, quality assessed trials,
entered data into Meta-View 4.1, entered all study details into Review Manager 4.1, and co-wrote the review; Jeffrey Carson (Robert
Wood Johnson Medical School) provided expert opinion, co-wrote review; Paul Hebert (Ottawa General Hosptial) provided expert
opinion; David Henry (Institute of Clinical Evaluative Sciences) co-wrote review; Katharine Ker (London School of Hygiene &Tropical
Medicine) undertook the following tasks for the 2010 update - screened search output, obtained articles, applied inclusion/exclusion
criteria to retrieved papers, assessed risk of bias, extracted data, performed data analysis and revised the text of the review; Brian
McClelland (Scottish National Blood Transfusion Service) provided expert opinion.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• NSW Ministerial Advisory Committee on Quality in Health Care, Australia.
• NSW Health Department, Australia.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Erythrocyte Transfusion [adverse effects; mortality; ∗standards]; Guidelines as Topic; Hemoglobin A [analysis]; Randomized Controlled
Trials as Topic; Reference Values; Transplantation, Autologous; Transplantation, Homologous
MeSH check words
Humans
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